BOSTON – Troutman Pepper Locke advised Eupraxia Pharmaceuticals, Inc. (Eupraxia) (NASDAQ: EPRX; TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology designed to optimize local, controlled drug delivery for applications with significant unmet need, in the closing of its $63.2 million public offering of common shares and pre-funded warrants. For more information, see the press release.
The offering consists of 7,607,145 common shares of the company, which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of $7 per common share, and pre-funded warrants to purchase up to 1,428,571 common shares in lieu thereof, the pre-funded warrants at a price of $6.99999 per pre-funded warrant.
The Troutman Pepper Locke team that advised Eupraxia was led by Tom Rose, Shona Smith, Mark Goldsmith, Judy O’Grady, Noreen Onimus, Jason Langford, Joe Cataldo, and Codi Royall.
Consistently recognized as a top-tier practice, Troutman Pepper Locke’s corporate attorneys regularly handle strategic deals for clients ranging from industry leading, Fortune 100 corporations to emerging companies. Core areas of service include mergers and acquisitions, corporate finance, corporate governance, securities laws compliance, capital markets transactions, and other significant domestic and cross-border transactions, as well as general corporate counseling.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.